Kornimate/medical-research-clean huggingface dataset:
spirometry and methacholine challenge test in asthmatic children age 3-6years

Conditions: Asthma; Recurrent Cough

Summary: rational: the possible contribution of methacholine challenge test via spirometry to the clinical diagnosis of young children with various respiratory symptoms, the most appropriate spirometry index, and the proper cutoff point concentration that will define airway sensitivity have not yet been explored. objectives: to assess airway reactivity by spirometry in a large group of children aged 3-6years with various respiratory symptoms.

we aimed to gather information concerning methacholine challenge test performed in children previously diagnosed with asthma (asthmatics) and 48 had prolonged cough (coughers) from the pediatric clinic at meyer children's hospital. tests were performed by inhalation of triple-concentration increments (0.06 to13.9mg/ml/methacholine). spirometry was determined at baseline and after each inhalation in duplicate sets. end of test was defined by a fall of 20%fev1 baseline (pc20-fev1). pc20-fev1\<4.0mg/ml was considered positive). results from the challenge were related to data from questionnaires concerning respiratory symptoms were analyzed at the end of the studies.

Eligibility criteria:
inclusion criteria: * age 3- to 6-years * respiratory diseases who were highly indicative of asthma diagnosis according to gina guidelines \[9\] * cough duration of more than 4 weeks * normal chest auscultation and baseline fev1\>75% predicted for healthy preschool children, on the day of testing. exclusion criteria: * presence of other chronic respiratory conditions * emergency room visit or the presence of respiratory infection within the last month * oral or inhaled steroids or other anti-inflammatory medication taken in the last two weeks * bronchodilator taken within 24-hours prior to the test.

Keywords: methacholine challenge; spirometry, early childhood
the edi level and cardiopulmonary function between hhhfnc and unheated humidified high-flow oxygen mask in copd

Conditions: Chronic Obstructive Lung Disease; Respiratory Insufficiency

Summary: patients with copd exacerbation usually need respiratory support after extubation. recently, hhhfnc has been used in both adult and neonates with post-extubation respiratory support. studies indicate that hhhfnc has seminar efficacy compared to non-invasive positive pressure ventilation and superior than conventional oxygen therapy. there are no clinical data of diaphragm electrical activity and cardiopulmonary function for using hhhfnc and uhfom as post-extubation respiratory support.

objectives： the aim of this study is to compare the edi level and cardiopulmonary parameters between heated humidified high-flow nasal cannula (hhhfnc) versus unheated high-flow oxygen mask (uhfom) in acute exacerbation of chronic obstructive pulmonary disease (copd) patients with post-extubation respiratory support. this is the first clinical trial to investigate and analysis the variations of cardiopulmonary parameters and edi level between hhhfnc and uhfom in adult patients.

Eligibility criteria:
inclusion criteria: 1. ae of copd received intubation and ready to be weaning 2. p/f ratio \> 200 during sbt before extubation exclusion criteria: 1. unable to insert ng tube 2. refuse to re-intubated when respiratory failure after extubation 3. planned niv use after extubation 4. pregnancy
hyaluronic acid in overuse knee pain

Conditions: Overuse Injury

Summary: sports activity represents part of day living people, a knee pain originated by high demand joint activity could represent a limitation to continue sports. the aim of this clinical trial is demonstrate the effects of hyaluronic acid in sportsmen with knee pain.

sports activities have become a fundamental part of our daily life, this has led to an overuse of load joints, being the knee the most relevant. overuse injuries of the knee result from microtrauma associated with physical activity and exercise that exceeds the strength of the cartilage tissue. the purpose of this study is to evaluate the usefulness and safety of hyaluronic acid in athlete patients with knee overuse syndrome. investigators hypothesis is that hyaluronic acid y safe and can improve symptoms of knee pain in sports patients. . scores recorder data will be made at 15 days, then at 3 and 6 months after two knee injections of hyaluronic acid with sorbitol (synolis va). synolis va is a viscoelastic, sterile, non-pyrogenic, isotonic, buffered solution of 2% hyaluronic acid. the hyaluronic acid used in synolis va is obtained from bacterial fermentation and has a high molecular weight of 2 mdaltons, it has a neutral ph of 6.8 - 7.4 like synovial fluid. high concentration and high molecular weight of hyaluronic acid combined with sorbitol limits its degradation and confers the capacity of viscoelastic solution to restore joint lubrication and shock absorption properties. this research protocol has been approve by the ethics and research institutional committee in issemym tlalnepantla estado de mexico number: cei/0504/pi./2022. all participants must sign a informed consent to confirm be part fo this study.

Eligibility criteria:
inclusion criteria: * - patients with knee pain for more than 3 months * patients between 30 and 55 years old * patients without a history of previous knee joint surgery. * patients without chronic-degenerative diseases such as diabetes, hypertension, rheumatoid arthritis or other autoimmune diseases. * patients who perform impact social sports at least 3 times a week for more than 1 hour in the last 3 months prior to treatment. * patients without a history of allergies to non-steroidal anti-inflammatory drugs. * patients with no history of infection in or around the knee. exclusion criteria: * - patients who cannot be categorized as social athletes. * patients with an associated sports injury that limits their sports practice. * patients who have a treatment associated with knee pain independent of that established in the study protocol.

Keywords: knee pain sportsmen hyaluronic acid
physical activity in ckd

Conditions: Chronic Kidney Diseases

Summary: the goal of this is to test the efficacy of a 12-week physical activity intervention in 64 adolescents with ckd.

for youth with chronic kidney disease (ckd), cardiovascular disease (cvd) is a leading cause of morbidity and early mortality. physical activity is a well-recognized determinant of health and quality of life, but, youth with ckd are less physically active than their healthy peers. identification of effective strategies to increase physical activity in youth with ckd is paramount to improving outcomes. the investigators will test the efficacy of a 12-week physical activity intervention in 64 adolescents with ckd. guided by the multiphase optimization strategy (most) framework, an optimization trial will identify intervention components that increase average daily moderate to vigorous physical activity by 15 min/day, a clinically meaningful increase. the components will be grounded in established behavioral change theories and be delivered via way to health, a web-based platform, to overcome barriers at the point of clinical care where time and resources are limited.

Eligibility criteria:
inclusion criteria: for adolescent participants: 1. males or females age 13 - 18 years 2. diagnosis of ckd stage ii - v not yet on dialysis or with a transplant 3. english proficiency 4. parental/guardian permission (informed consent), and if applicable, child assent for caregiver participants: 1. parent/legal guardian of an enrolled adolescent participant 2. english proficiency exclusion criteria: for adolescent participants: 1. pregnant or lactating 2. non-ambulatory 3. have high physical activity at baseline (\>45 min/day of mvpa) 4. provide \<2 days of physical activity data during the run-in period 5. have a condition, such as heart or lung disease, that preclude safely engaging in physical activity 6. have received a solid organ transplant 7. have limited english proficiency 8. are on dialysis 9. in the opinion of the investigator, are unable to comply with the requirements of the study protocol or are unsuitable for the study for any reason for caregivers participants: 1. limited english proficiency

Keywords: chronic kidney disease ckd
checking wether the m-ala cream could mark correctly the borders of bcc's tumors

Conditions: Basal Cell Carcinoma

Summary: correlation between mohs surgery and microscopic fluorescence photometry in determination of histological borders in basal cell carcinoma .

background: basal cell carcinoma (bcc) is the most common form of nonmelanoma skin cancer worldwide. bccs are slow-growing, locally invasive tumors that rarely metastasize but can cause extensive morbidity through local tissue destruction. recurrence is often the consequence of incomplete removal of the cancer tissue. mohs' micrographic surgery is considered the most effective treatment modality for bcc with a recurrence rate of less than 5 %, however, the technique requires specialized training and is labor-intensive and costly. fluorescence imaging by topical application of a tumor-localizing agent such as methyl 5-aminolevulinic acid (mal), resulting in buildup of photosensitizing porphyrin ix (ppix) that can be visualized by woods' light fluorescence, might serve as a quick and simple "bed-side" technique for demarcation of bcc tumor borders prior to surgical excision objective: to test the reliability of mal-induced porphyrin fluorescence tumor demarcation by comparison with the tumor borders determined by mohs' surgery methods: twenty eight patients with facial bccs (17 nodular, 3 superficial, 1 morphea type, 3 ulcerated and 4 recurrent tumors) scheduled for mohs' surgery were recruited for the study. the night before the surgical procedure, crusts were gently removed and an approximately 1 mm thick layer of a cream containing 16 % mal (metvixr) was applied to the tumor area as well as to the surrounding skin and covered by a transparent occlusive dressing. the following morning (10-17 hours after metvixr application), the dressing was removed, and the lesion size was determined with a caliber by measuring the largest perpendicular diameters under natural (clinical size) and woods' (fluorescence size) illumination. the patients then underwent the scheduled mohs' surgical procedure, and the tumor size (mohs' size) was determined when reaching the tumor free margins.

Eligibility criteria:
inclusion criteria: * a- bove 18 years exclusion criteria: * childern * pregnant women

Keywords: bcc
ncrt combined with sequential perioperative pd-1 inhibitor for laescc

Conditions: Esophageal Squamous Cell Carcinoma (ESCC)

Summary: this study aims to examine the efficacy of the combination of neoadjuvant chemoradiotherapy and perioperative pd-1 inhibitor in patients with locally advanced esophageal squamous cell cancer and explore the predictive biomarkers for this regimen.


Eligibility criteria:
inclusion criteria: * 18-75 years old * histologically or cytologically confirmed esophageal squamous cell cancer * stage t3-4an0m0 or tanyn1-3m0 according to the american joint committee on cancer staging manual eighth edition * eastern cooperative oncology group performance status of 0 or 1 * he indexes of hematology, biochemistry and organ function meet the following requirements: a. white blood cell count (wbc) ≥ 3.0×109/l；b. neutrophil count (anc) ≥ 1.5×109/l; c. platelets ≥ 85×109/l; d. hemoglobin ≥ 90g/l; e. total bilirubin ≤ 1.5 uln; f. alt ≤ 1.5 uln; g. creatinine clearance rate \>60 ml/min; * the cardiopulmonary function needs to meet the following criteria: ef ≥ 55%, vc \> 60%, fev1 \> 1.2l, fev1%\> 40%, dlco \> 40% * women of childbearing age must undergo a pregnancy test within 7 days before enrollment for treatment, and only those with a negative result can be enrolled * voluntarily participating in this study exclusion criteria: * patients with active infection within 2 weeks before the first use of the study drug * a history of interstitial lung disease or non-infectious pneumonia * a history of autoimmune diseases or abnormal immune system * patients who cannot tolerate chemoradiotherapy or surgery due to severe cardiac, lung dysfunction * patients diagnosed with any other malignant tumor within 5 years before enrollment, except for malignant tumors with low risk of recurrence and risk of death, such as fully treated basal cell or squamous cell skin and carcinoma in situ of the cervix; * known or suspected allergy or hypersensitivity to monoclonal antibodies, any ingredients of toripalimab, and the chemotherapeutic drugs nab-paclitaxel or cisplatin * a history of immunodeficiency，including a positive hiv test result or other acquired or congenital immunodeficiency diseases, a history of organ transplantation or allogeneic bone marrow transplantation * women during pregnancy or lactation * other situations not suitable for enrollment

Keywords: esophageal squamous cell cancer neoadjuvant chemoradiotherapy perioperative immunotherapy pd-1 inhibitor
efficacy of a preoperative anaemia clinic in patients undergoing elective abdominal surgery

Conditions: Anemia, Iron-Deficiency

Summary: efficacy of a preoperative anaemia clinic in patients undergoing elective abdominal surgery diagnosed with iron deficieny anaemia

objective: this study aims to investigate how preoperative intravenous iron treatment affects hemoglobin elevations in patients undergoing elective abdominal surgery diagnosed with iron deficiency anaemia and when treatment should be administrated for optimal effect. methods: the study is a prospective, descriptive cohort study, where patients are included from a quality improvement project at the departments of abdominal surgery and the department of anesthesia, centre for cancer and organ disease at rigshospitalet in denmark. patients undergoing elective abdominal surgery will be screened for iron deficiency anaemia 1-4 weeks prior to surgery and patients diagnosed with iron deficiency anaemia will be included. intravenous iron infusion will be administrated preoperatively and hb will be measured 1-2 days prior to surgery or on day of surgery. the preparation used is ferric derisomaltose (monofer, pharmacosmos a/s, holbæk, denmark) with a max single iron dose of 20 mg/kg. the dose administrated is calculated using patient bodyweight and hb value and administered ≥30 minutes followed by 30 minutes observation including monitoring with 3-lead ecg and pulsoximitri. study results will be sought to be published in an international peer-reviewed journal.

Eligibility criteria:
inclusion criteria: * all patients diagnosed with preoperative iron deficiency anaemia * all patients receiving preoperative or postoperative intravenous iron infusion * patients undergoing elective abdominal surgery exclusion criteria: * patients missing hb values after intravenous iron infusion prior to surgery * patients undergoing acute abdominal surgery
biomark study: predict intravenous immunoglobulin responders in chronic inflammatory demyelinating polyradiculoneuropathy

Conditions: CIDP

Summary: this study aims analyze the transcriptome to identify predictive biomarkers of ivig in cidp patients. 25 patients with a diagnosis of cidp according to european criteria, naïve of treatment, will be included and followed for 1 year. clinical assessment (rt-mrc ; martin vigorimeter, rt-miss,r-ods,tw25, 9hole-peg test) will be performed at baseline and at 3, 6 and 12 months after the first ivig course. responder/no responder status will be defined at 3 month and confirmed at 12 months. blood samples will be collected before the ivig course at baseline, and at 2months and 6 months. at the end of the first ivig course a blood sample will be collected to assess early changes of transcriptome. the cidp diagnosis and responder/no responder status will be confirmed by an independent committee. the transcriptome of the patients will be individually analyzed and compared regarding responder/non responder status to a control groups of 20 healthy subjects


Eligibility criteria:
inclusion criteria: * chronic inflammatory demyelinating polyradiculoneuropathy (according to european criterions) * first line of treatment * treatment with intravenous immunoglobulin required * healthy subjects matched for age and gender exclusion criteria: for cidp patients * uncontrolled diabetes, monoclonal spike with anti-ganglioside activity, anti myelin-associated glycoprotein antibodies, hiv infection, hbv infection, hcv infection, connective tissue disease, hemopathy, evolutive disease) for healthy subjects: any chronic or autoimmune disease for all subjets viral or bacterial infection in the last 30 days chemotherapy in the last 5 years immunosuppressive therapy

Keywords: biomarker cidp ivig treatment response
the effect of electroacupuncture on nerve pain caused by chemotherapy (chemotherapy-induced peripheral neuropathy)

Conditions: Chemotherapy-induced Peripheral Neuropathy; Nerve Pain; Neuropathy; Neuropathy, Painful; Pain; CIPN - Chemotherapy-Induced Peripheral Neuropathy

Summary: this study is a randomized controlled trial of electroacupuncture (referred to as ea) versus sham acupuncture (referred to as ea) as effective treatments for chemotherapy-induced peripheral neuropathy/cipn pain in cancer survivors.

during the study, patients will be randomized to one of the two possible acupuncture treatment groups and receive 10 treatments over the course of 8 weeks and then enter a follow-up period. acupuncture is a medical technique that involves insertion of very thin needles into specific areas on the body with the goal of promoting health and well-being. ea involves adding a very small amount of electricity through the acupuncture needles (electrical stimulation). researchers have found that ea can increase the effects of regular acupuncture, and it is particularly helpful for treating different kinds of pain. the purpose of this study is to learn if ea can improve cipn pain in cancer survivors, and if it is effective against other cipn-related symptoms.

Eligibility criteria:
inclusion criteria: * english-proficient men and women aged ≥18 years * free of oncologic disease by clinical examination and history * completed neurotoxic chemotherapy such as platinum agents, taxanes, vinca alkaloids, and bortezomib at least three months prior to enrollment * diagnosis of cipn based on symptom history, loss of deep tendon reflexes, or the presence of symmetrical stocking-glove pain, numbness, or paresthesia73 * grade ≥1 sensory pain based on the nci common terminology criteria for adverse events (ctcae) version 5.0 * self-reported moderate to severe cipn pain, as defined by a score of 4 or greater on the bpi-sf average pain item over the past week * on a stable regimen (no change in the past three months) if taking anti-neuropathy or other pain medications * willing to adhere to requirement that no new pain medication be taken throughout the first 12 weeks of the study period * willing to adhere to all study-related procedures, including randomization to one of the two possible acupuncture treatments exclusion criteria: * patients with a pacemaker or other electronically charged medical device * use of acupuncture for symptom management within the past 12 months

Keywords: chemotherapy-induced peripheral neuropathy cipn electroacupuncture cancer survivor acupuncture memorial sloan kettering cancer center neuropathy dana-farber cancer institute neuropathic pain pain management
a pilot study of cognitive-behavioral therapy for rumination disorder (cbt-rd)

Conditions: Rumination Disorder

Summary: the primary aim of this study is to pilot cognitive behavioral therapy (cbt-rd) for 10 individuals ages 10 and older who have rumination disorder

rumination disorder (rd; also known as "rumination syndrome") is characterized by the repeated regurgitation of food during or soon after eating, which typically occurs at least a few times per week, frequently daily, with subsequent re-chewing, re-swallowing, or spitting out of the regurgitated material. diaphragmatic breathing is a widely used technique for rumination as a competing response to the abdominal wall contraction hypothesized to trigger regurgitation. however, the efficacy of diaphragmatic breathing remains unknown and has mainly been delivered simply through a one-session instruction with an occasional follow-up. in the absence of evidence-based treatments for rd, dr. jennifer thomas has contributed to the creation of a manualized treatment, cognitive-behavioral therapy for rumination disorder (cbt-rd) informed by published case reports and currently in use at the eating disorders clinical and research program (edcrp) at massachusetts general hospital and the psychological services center at drexel university. cbt-rd targets the habitual contraction of the abdominal wall and preceding events through the use of habit reversal, using primarily diaphragmatic breathing as a competing response. this study involves a phone screen to determine eligibility, followed by 5-8 sessions of cbt-rd (approximately 50 minutes each). a battery of questionnaires will be administered at pre-treatment, post-treatment, and 3-month follow-up intervals.

Eligibility criteria:
inclusion criteria: * age 10 or above * experience repeated regurgitation of food during or soon after eating, consistent with rumination disorder * if applicable, have stable psychiatric medication for the past three months exclusion criteria: * currently engage (in past three months) in any regular compensatory behaviors (e.g., self-induced vomiting, laxative/diuretic use) * current diagnosis of anorexia nervosa * acute suicide risk * are currently receiving psychological treatment for rumination disorder * co-morbid clinically significant psychological disorder that would require attention beyond the study treatment (e.g., psychotic disorder, substance dependence) * current pregnancy
basiliximab maintenance in ulcerative colitis

Conditions: Ulcerative Colitis

Summary: primary objective safety: assess the safety of basiliximab 40 mg, given every 4 weeks, in subjects with ulcerative colitis who completed previous basiliximab studies. secondary objectives: evaluate the efficacy and assess the immunogenicity of this multiple-dose maintenance regimen in this population


Eligibility criteria:
inclusion criteria: 1. previously met eligibility criteria in the previous basiliximab uc study 2. must have a total mayo score at entry consistent with clinical response or clinical remission. 3. signed a current irb/iec-approved informed consent form 4. females of childbearing potential must use an effective birth control method, and be willing to continue birth control during the study, and for 4 months after the last dose of study drug. 5. females of non-childbearing potential should be surgically sterile (bilateral tubal ligation with surgery at least 6 months before study entry, hysterectomy, or bilateral oophorectomy at least 2 months before study entry) or post-menopausal for at least 2 years. exclusion criteria: 1. subject is severely ill, as evidenced by more than 6 episodes of loose stools, all of them bloody, during a 24-hour period within the prior 7 days, concurrent with any of the following systemic features: * heart rate \> 90 beats/min at rest * temperature \> 37.8 degrees c * hemoglobin \< 10.5 g/dl 2. subject is currently receiving a restricted/prohibited concomitant medication 3. subject has undergone colectomy (total, or subtotal) 4. subject is pregnant or breast-feeding 5. prior noncompliance with previous study visit schedule and requirements

Keywords: ulcerative colitis